Skip to search formSkip to main contentSkip to account menu

PTK787/ZK 222584

Known as: PTK787/ZK-222584, PTK787/ZK222584 
National Institutes of Health

Related topics

Related topics

4 relations
CGP79787DPTK 787Vascular Endothelial Growth Factor A

Broader (1)

vatalanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma
Purpose: To measure changes in tumor blood flow following treatment with PTK787/ZK 222584, a pan–vascular endothelial growth… 
Highly Cited
2006
Highly Cited
2006
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
FTY720, a potent immunomodulator, becomes phosphorylated in vivo (FTY-P) and interacts with sphingosine-1-phosphate (S1P… 
Highly Cited
2005
Highly Cited
2005
A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5…
LBA3 Background: PTK787/ZK 222584 (PTK/ZK) is a novel, oral, small molecule, anti-angiogenesis compound that blocks tyrosine… 
Highly Cited
2005
Highly Cited
2005
The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade
Purpose: Receptor tyrosine kinases of the ErbB family play important roles in the control of tumor growth. Vascular endothelial… 
Highly Cited
2004
Highly Cited
2004
The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor…
Chromatin remodeling agents such as histone deacetylase inhibitors have been shown to modulate gene expression in tumor cells and… 
Highly Cited
2004
Highly Cited
2004
Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis
AbstractObjective and design: To examine the effects of PTK787/ZK222584, a novel angiogenesis inhibitor, in a series of in vivo… 
Review
2003
Review
2003
VEGF blocking therapy in the treatment of cancer
It is widely accepted that tumour growth beyond a few cubic millimetres cannot occur without the induction of a new vascular… 
Highly Cited
2001
Highly Cited
2001
Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
The vascular endothelial growth factor (VEGF) receptor is a major target for anti-angiogenesis-based cancer treatment. Here we… 
Highly Cited
2000
Highly Cited
2000
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell…
Antiangiogenic therapy is a promising new strategy to inhibit tumor growth and formation of metastases. Vascular endothelial… 
Highly Cited
2000
Highly Cited
2000
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Malignant pleural effusion (PE) is associated with advanced human lung cancer. We found recently, using a nude mouse model, that… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)